Baxter to Present at the UBS Global Life Sciences Conference

DEERFIELD, Ill.--(BUSINESS WIRE)-- Baxter International Inc. (NYSE: BAX) announced today that it will present at the UBS Global Life Sciences Conference on Wednesday, September 22, 2010 at 8:00 a.m. (ET) or 7:00 a.m. (CT).

The live webcast of Baxter's presentation can be accessed from the Baxter corporate website at www.baxter.com and will be available for replay through October 22, 2010.

Baxter International Inc. develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.



CONTACT:

Baxter International Inc.
Investor Relations:
Mary Kay Ladone, +1-847-948-3371
or
Media:
Deborah Spak, +1-847-948-2349

KEYWORDS:   United States  North America  Illinois

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases  Medical Devices  Pharmaceutical  Other Science  Medical Supplies  Science

MEDIA:

Logo
 Logo

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.